Original data (with adjusted standard errors for multi-arm studies):

              treat1      treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
4           BZD-long   BZD-short -0.3034 0.2576     0.2576     0.3042     2         
5            placebo    zolpidem -0.4505 0.1385     0.2224     0.2780     3        *
5           zaleplon    zolpidem -0.1712 0.1104     0.1223     0.2323     3        *
5            placebo    zaleplon -0.2793 0.1142     0.1279     0.2367     3        *
6        eszopiclone     placebo  0.4040 0.1026     0.1026     0.1917     2         
9          BZD-short   zopiclone  0.2617 0.2826     0.2826     0.3257     2         
24         BZD-short     placebo  1.1829 0.3131     0.3131     0.3525     2         
32           placebo    zaleplon  0.0294 0.1195     0.1369     0.2404     3        *
32          zaleplon    zolpidem -0.3039 0.1235     0.1439     0.2455     3        *
32           placebo    zolpidem -0.2745 0.1402     0.1978     0.2738     3        *
34           placebo   zopiclone -0.7932 0.0971     0.0971     0.1888     2         
36  BZD-intermediate     placebo  0.7540 0.1612     0.1612     0.2285     2         
44  BZD-intermediate     placebo  1.3538 0.2862     0.2862     0.3289     2         
48          zaleplon    zolpidem -0.1046 0.1337     0.1337     0.2100     2         
50  BZD-intermediate    zolpidem -0.6721 0.3211     0.3211     0.3596     2         
60           doxepin     placebo  0.4235 0.1788     0.1788     0.2412     2         
70         melatonin     placebo -0.5156 0.3214     0.3214     0.3599     2         
72          BZD-long   BZD-short -0.0000 0.4082     0.5000     0.5379     3        *
72         BZD-short     placebo  0.0000 0.4082     0.5000     0.5379     3        *
72          BZD-long     placebo  0.0000 0.4082     0.5000     0.5379     3        *
73          BZD-long     placebo  0.6870 0.2658     0.2658     0.3113     2         
74          BZD-long   BZD-short -0.3055 0.3181     0.3181     0.3569     2         
77       eszopiclone     placebo  0.6503 0.1286     0.1286     0.2068     2         
80           placebo    zolpidem -1.1824 0.6258     0.6258     0.6464     2         
81           placebo    zolpidem -1.1706 0.6248     0.6248     0.6455     2         
100        melatonin     placebo  0.1894 0.1894     0.1894     0.2492     2         
104         BZD-long     placebo  0.7143 0.2757     0.2757     0.3197     2         
119          placebo    zolpidem -0.1815 0.2988     0.2988     0.3399     2         
120      eszopiclone     placebo  0.3387 0.1392     0.1392     0.2135     2         
127          placebo   ramelteon -0.1953 0.0651     0.0651     0.1745     2         
129        melatonin     placebo  0.1351 0.1096     0.1096     0.1955     2         
130        melatonin     placebo  0.0887 0.0833     0.0833     0.1821     2         
136      eszopiclone     placebo  0.7984 0.0760     0.0760     0.1789     2         
137          placebo    zolpidem -0.4431 0.1440     0.1440     0.2167     2         
143 BZD-intermediate   BZD-short -0.1607 0.1293     0.1293     0.2072     2         
145          placebo   ramelteon -0.1428 0.1219     0.1219     0.2027     2         
162          placebo  quetiapine -0.0506 0.5564     0.5564     0.5795     2         
164 BZD-intermediate mirtazapine -0.3261 0.2374     0.2374     0.2873     2         

Number of treatment arms (by study):
    narms
4       2
5       3
6       2
9       2
24      2
32      3
34      2
36      2
44      2
48      2
50      2
60      2
70      2
72      3
73      2
74      2
77      2
80      2
81      2
100     2
104     2
119     2
120     2
127     2
129     2
130     2
136     2
137     2
143     2
145     2
162     2
164     2

Results (fixed effects model):

              treat1      treat2     SMD             95%-CI    Q leverage
4           BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.01     0.31
5            placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.01        .
5           zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.23        .
5            placebo    zaleplon -0.2003 [-0.3445; -0.0560] 0.38        .
6        eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 4.18     0.25
9          BZD-short   zopiclone  0.1218 [-0.1540;  0.3976] 0.24     0.25
24         BZD-short     placebo  0.8985 [ 0.6648;  1.1321] 0.82     0.14
32           placebo    zaleplon -0.2003 [-0.3445; -0.0560] 2.81        .
32          zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.26        .
32           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.62        .
34           placebo   zopiclone -0.7767 [-0.9583; -0.5951] 0.03     0.91
36  BZD-intermediate     placebo  0.7265 [ 0.5127;  0.9404] 0.03     0.46
44  BZD-intermediate     placebo  0.7265 [ 0.5127;  0.9404] 4.80     0.15
48          zaleplon    zolpidem -0.2303 [-0.3598; -0.1009] 0.88     0.24
50  BZD-intermediate    zolpidem  0.2959 [ 0.0479;  0.5439] 9.09     0.16
60           doxepin     placebo  0.4235 [ 0.0730;  0.7740] 0.00     1.00
70         melatonin     placebo  0.0918 [-0.0286;  0.2122] 3.57     0.04
72          BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.30        .
72         BZD-short     placebo  0.8985 [ 0.6648;  1.1321] 3.23        .
72          BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 1.55        .
73          BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 0.06     0.28
74          BZD-long   BZD-short -0.2755 [-0.5556;  0.0047] 0.01     0.20
77       eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 0.08     0.16
80           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 1.44     0.01
81           placebo    zolpidem -0.4306 [-0.5738; -0.2875] 1.40     0.01
100        melatonin     placebo  0.0918 [-0.0286;  0.2122] 0.27     0.11
104         BZD-long     placebo  0.6230 [ 0.3467;  0.8993] 0.11     0.26
119          placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.70     0.06
120      eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 3.91     0.14
127          placebo   ramelteon -0.1837 [-0.2963; -0.0710] 0.03     0.78
129        melatonin     placebo  0.0918 [-0.0286;  0.2122] 0.16     0.31
130        melatonin     placebo  0.0918 [-0.0286;  0.2122] 0.00     0.54
136      eszopiclone     placebo  0.6138 [ 0.5133;  0.7143] 5.90     0.46
137          placebo    zolpidem -0.4306 [-0.5738; -0.2875] 0.01     0.26
143 BZD-intermediate   BZD-short -0.1720 [-0.3859;  0.0419] 0.01     0.71
145          placebo   ramelteon -0.1837 [-0.2963; -0.0710] 0.11     0.22
162          placebo  quetiapine -0.0506 [-1.1412;  1.0400] 0.00     1.00
164 BZD-intermediate mirtazapine -0.3261 [-0.7913;  0.1391] 0.00     1.00

Results (random effects model):

              treat1      treat2     SMD             95%-CI
4           BZD-long   BZD-short -0.2716 [-0.5992;  0.0560]
5            placebo    zolpidem -0.4814 [-0.6887; -0.2741]
5           zaleplon    zolpidem -0.2478 [-0.4657; -0.0299]
5            placebo    zaleplon -0.2336 [-0.4743;  0.0071]
6        eszopiclone     placebo  0.5645 [ 0.3721;  0.7568]
9          BZD-short   zopiclone  0.1331 [-0.2559;  0.5222]
24         BZD-short     placebo  0.8831 [ 0.5878;  1.1785]
32           placebo    zaleplon -0.2336 [-0.4743;  0.0071]
32          zaleplon    zolpidem -0.2478 [-0.4657; -0.0299]
32           placebo    zolpidem -0.4814 [-0.6887; -0.2741]
34           placebo   zopiclone -0.7500 [-1.0786; -0.4214]
36  BZD-intermediate     placebo  0.7120 [ 0.4308;  0.9933]
44  BZD-intermediate     placebo  0.7120 [ 0.4308;  0.9933]
48          zaleplon    zolpidem -0.2478 [-0.4657; -0.0299]
50  BZD-intermediate    zolpidem  0.2306 [-0.0989;  0.5601]
60           doxepin     placebo  0.4235 [-0.0494;  0.8963]
70         melatonin     placebo  0.0659 [-0.1531;  0.2848]
72          BZD-long   BZD-short -0.2716 [-0.5992;  0.0560]
72         BZD-short     placebo  0.8831 [ 0.5878;  1.1785]
72          BZD-long     placebo  0.6115 [ 0.2882;  0.9349]
73          BZD-long     placebo  0.6115 [ 0.2882;  0.9349]
74          BZD-long   BZD-short -0.2716 [-0.5992;  0.0560]
77       eszopiclone     placebo  0.5645 [ 0.3721;  0.7568]
80           placebo    zolpidem -0.4814 [-0.6887; -0.2741]
81           placebo    zolpidem -0.4814 [-0.6887; -0.2741]
100        melatonin     placebo  0.0659 [-0.1531;  0.2848]
104         BZD-long     placebo  0.6115 [ 0.2882;  0.9349]
119          placebo    zolpidem -0.4814 [-0.6887; -0.2741]
120      eszopiclone     placebo  0.5645 [ 0.3721;  0.7568]
127          placebo   ramelteon -0.1730 [-0.4322;  0.0862]
129        melatonin     placebo  0.0659 [-0.1531;  0.2848]
130        melatonin     placebo  0.0659 [-0.1531;  0.2848]
136      eszopiclone     placebo  0.5645 [ 0.3721;  0.7568]
137          placebo    zolpidem -0.4814 [-0.6887; -0.2741]
143 BZD-intermediate   BZD-short -0.1711 [-0.4828;  0.1406]
145          placebo   ramelteon -0.1730 [-0.4322;  0.0862]
162          placebo  quetiapine -0.0506 [-1.1864;  1.0852]
164 BZD-intermediate mirtazapine -0.3261 [-0.8892;  0.2371]

Number of studies: k = 32
Number of pairwise comparisons: m = 38
Number of observations: o = 6966
Number of treatments: n = 13
Number of designs: d = 18

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI     z  p-value
BZD-intermediate 0.7265 [ 0.5127; 0.9404]  6.66 < 0.0001
BZD-long         0.6230 [ 0.3467; 0.8993]  4.42 < 0.0001
BZD-short        0.8985 [ 0.6648; 1.1321]  7.54 < 0.0001
doxepin          0.4235 [ 0.0730; 0.7740]  2.37   0.0179
eszopiclone      0.6138 [ 0.5133; 0.7143] 11.97 < 0.0001
melatonin        0.0918 [-0.0286; 0.2122]  1.49   0.1352
mirtazapine      1.0526 [ 0.5406; 1.5646]  4.03 < 0.0001
placebo               .                 .     .        .
quetiapine       0.0506 [-1.0400; 1.1412]  0.09   0.9275
ramelteon        0.1837 [ 0.0710; 0.2963]  3.20   0.0014
zaleplon         0.2003 [ 0.0560; 0.3445]  2.72   0.0065
zolpidem         0.4306 [ 0.2875; 0.5738]  5.90 < 0.0001
zopiclone        0.7767 [ 0.5951; 0.9583]  8.38 < 0.0001

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI    z  p-value            95%-PI
BZD-intermediate 0.7120 [ 0.4308; 0.9933] 4.96 < 0.0001 [ 0.2634; 1.1607]
BZD-long         0.6115 [ 0.2882; 0.9349] 3.71   0.0002 [ 0.1322; 1.0909]
BZD-short        0.8831 [ 0.5878; 1.1785] 5.86 < 0.0001 [ 0.4244; 1.3419]
doxepin          0.4235 [-0.0494; 0.8963] 1.76   0.0792 [-0.1791; 1.0260]
eszopiclone      0.5645 [ 0.3721; 0.7568] 5.75 < 0.0001 [ 0.1718; 0.9571]
melatonin        0.0659 [-0.1531; 0.2848] 0.59   0.5554 [-0.3421; 0.4738]
mirtazapine      1.0381 [ 0.4087; 1.6675] 3.23   0.0012 [ 0.2922; 1.7840]
placebo               .                 .    .        .                 .
quetiapine       0.0506 [-1.0852; 1.1864] 0.09   0.9304 [-1.1972; 1.2985]
ramelteon        0.1730 [-0.0862; 0.4322] 1.31   0.1909 [-0.2606; 0.6065]
zaleplon         0.2336 [-0.0071; 0.4743] 1.90   0.0571 [-0.1878; 0.6551]
zolpidem         0.4814 [ 0.2741; 0.6887] 4.55 < 0.0001 [ 0.0804; 0.8825]
zopiclone        0.7500 [ 0.4214; 1.0786] 4.47 < 0.0001 [ 0.2667; 1.2334]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0262; tau = 0.1619; I^2 = 51.3% [22.3%; 69.5%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f. p-value
Total           47.25   23  0.0021
Within designs  28.61   15  0.0180
Between designs 18.65    8  0.0169
[1] "A total of 13 treatments are included in the network."
[1] "A total of 32 studies are included in this analysis."
[1] "Estimated heterogeneity tau-squared0.03"
[1] "Global test for inconsistency, p-value 0.01688 (Q=19, d.o.f. 8)"
[1] "File created on 2022-01-30"
